| 篇名 | 作者 | 刊名 | 出版年 | 查看 |
|---|
| Histological and anatomic changes in Barrett's esophagus after antirefluxsurgery |
Low, D.E.;Levine, D.S.;Dail, D.H.;Kozarek, R.A.; |
The American Journal of Gastroenterology |
1999-01-01 |
查看 |
| Optimizing endoscopic biopsy detection of early cancers in Barrett'shigh-grade dysplasia |
Reid, B.J.;Blount, P.L.;Feng, Z.;Levine, D.S.; |
The American Journal of Gastroenterology |
2000-11-01 |
查看 |
| Safety of a systematic endoscopic biopsy protocol in patients withBarrett's esophagus |
Levine, D.S.;Blount, P.L.;Rudolph, R.E.;Reid, B.J.; |
The American Journal of Gastroenterology |
2000-05-01 |
查看 |
| Safety of a systematic endoscopic biopsy protocol in patients withBarrett's esophagus |
Levine, D.S.;Blount, P.L.;Rudolph, R.E.;Reid, B.J.; |
The American Journal of Gastroenterology |
2000-05-01 |
查看 |
| Predictors of progression to cancer in Barrett's esophagus: baselinehistology and flow cytometry identify low- and high-risk patient subsets |
Reid, B.J.;Levine, D.S.;Longton, G.;Blount, P.L.;Rabinovitch, P.S.; |
The American Journal of Gastroenterology |
2000-07-01 |
查看 |
| Predictors of progression to cancer in Barrett's esophagus: baselinehistology and flow cytometry identify low- and high-risk patient subsets |
Reid, B.J.;Levine, D.S.;Longton, G.;Blount, P.L.;Rabinovitch, P.S.; |
The American Journal of Gastroenterology |
2000-07-01 |
查看 |
| Predictors of progression in Barrett's esophagus II: baseline 17p (p53)loss of heterozygosity identifies a patient subset at increased risk forneoplastic progression |
Reid, B.J.;Prevo, L.J.;Galipeau, P.C.;Sanchez, C.A.;Longton, G.;Levine, D.S.;Blount, P.L.;Rabinovitch, P.S.; |
The American Journal of Gastroenterology |
2001-10-01 |
查看 |
| Predictors of progression in Barrett's esophagus III: baseline flowcytometric variables |
Rabinovitch, P.S.;Longton, G.;Blount, P.L.;Levine, D.S.;Reid, B.J.; |
The American Journal of Gastroenterology |
2001-11-01 |
查看 |
| A randomized, double blind, dose-response comparison of balsalazide (6.75g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment ofactive, mild-to-moderate ulcerative colitis^1 |
Levine, D.S.;Riff, D.S.;Pruitt, R.;Wruble, L.;Koval, G.;Sales, D.;Bell, J.K.;Johnson, L.K.; |
The American Journal of Gastroenterology |
2002-06-01 |
查看 |
| Effects of 6-12 months of esomeprazole treatment on the gastric mucosa |
Genta, R.M.;Rindi, G.;Fiocca, R.;Magner, D.J.;D'Amico, D.;Levine, D.S.; |
The American Journal of Gastroenterology |
2003-06-01 |
查看 |
|
|
